New therapies for neurodevelopmental epilepsy
Group Stéphane Auvin
Epilepsy remains a therapeutic challenge, with 20-30% of patients resistant to treatment. In children, epilepsy occurs in the developing brain and has cognitive and behavioral impacts. There are few treatments adapted to infants, despite the fact that this is the age at which the incidence is the highest.
Our project aims to develop treatments specifically targeting the neurodevelopmental features of neurotransmission, and to improve clinical trial methodologies for childhood epilepsy.
Our goal is to:
i) Control epileptic seizures
ii) Prevent their cognitive and behavioral consequences
We are also working on new clinical trial methodologies, one of the main obstacles to drug development for infants.
Members:
Stéphane Auvin (Professor – Hospital Practitioner), Blandine Dozière (Hospital Practitioner), Sarah Rozès Poblet (PhD student)
Recent publications:
Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open-label study extension of the SALIVA trial. Fayoux P, Dinomais M, Shaw H, Villain F, Schwartz D, Gautheron V, Letellier G, Auvin S. Dev Med Child Neurol. 2025 Jan 31. doi: 10.1111/dmcn.16251.
To what extent does status epilepticus contribute to brain damage in the developmental and epileptic Encephalopathies. Specchio N, Auvin S. Epilepsy Behav. 2025 Jan 29;164:110271. doi: 10.1016/j.yebeh.2025.110271.
Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches.Auvin S, Arzimanoglou A, Falip M, Striano P, Cross JH.. Epilepsia Open. 2025 Feb;10(1):85-106. doi: 10.1002/epi4.13075.
Pharmacotherapeutic strategies for drug-resistant epilepsy in children. Auvin S, Specchio N. Epilepsy Behav. 2024 Dec;161:110139. doi: 10.1016/j.yebeh.2024.110139.
Pharmacological management of prolonged seizures in Dravet syndrome including intravenous phenytoin. Abi Tayeh R, Dozières-Puyravel B, Arnaud L, Titomanlio L, Dauger S, Höhn S, Le Guern E, Auvin S. Epilepsia. 2024 Oct;65(10):e175-e181. doi: 10.1111/epi.18101.
WONOEP 2022: Neurotechnology for the diagnosis of epilepsy. Wagstyl K, Kobow K, Casillas-Espinosa PM, Cole AJ, Jiménez-Jiménez D, Nariai H, Baulac S, O’Brien T, Henshall DC, Akman O, Sankar R, Galanopoulou AS, Auvin S. Epilepsia. 2024 Aug;65(8):2238-2247. doi: 10.1111/epi.18028.
Contacts
Stéphane Auvin
Service de neurologie et maladies métaboliques & Inserm U1141
Hôpital Robert Debré
48 boulevard Sérurier
75019 Paris
stephane.auvin@aphp.fr
À lire aussi

Conference Dr. Boris Chaumette
Seminaire Dr Boris Chaumette

New Golgipathy identified in NeuroDev team
The NeuroDev team publishes an article in Life Science Alliance [1] identifying the first human pathogenic variant of GORASP1, the gene encoding the Golgi stacking protein GRASP65, and demonstrating its consequences on glycosylation and mitotic progression. [1] S....

Post-doc opportunity (1-2 years) within the group “Mitochondria and NDD” in the NeuroDev team
POSITION DESCRIPTION Postdoctoral position in the field of Neurosciences Type of contract: temporary position (CDD) Contract/project period: 1-2 years Expected date of employment: 1.04.2025 Proportion of work: 100% Workplace: Université Paris Cité, Inserm,...

Advancing psychiatry through Sleep and Chronobiology research
The “Mood” research axis of the SleepCmd team is dedicated to understanding the intricate links between sleep, circadian rhythms, and mood disorders such as depression, bipolar disorder, seasonal affective disorder, and suicide. Using state-of-the-art methods, the...